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Abstract: Zeolitic imidazolate framework (ZIF) hybrid fluores-
cent nanoparticles and ZIF antibody conjugates have been
synthesized, characterized, and employed in lateral-flow
immunoassay (LFIA). The bright fluorescence of the conju-
gates and the possibility to tailor their mobility gives a huge
potential for diagnostic assays. An enzyme-linked immuno-
sorbent assay (ELISA) with horseradish peroxidase (HRP) as
label, proved the integrity, stability, and dispersibility of the
antibody conjugates, LC-MS/MS provided evidence that a
covalent link was established between these metal-organic
frameworks and lysine residues in IgG antibodies.
Introduction
The confrontation with global infections requires the develop-
ment of robust, sensitive, and selective (bio)analytical tools with
good response time. Antibodies can provide the required
selectivity in fast analytical approaches. Yet, antibodies, in their
natural habitat, are generally protected from external factors,
such as ultraviolet radiation, dehydration, and high temper-
atures. Therefore, the use of antibodies in robust assays requires
them to be protected by a pseudo-skeleton.[1]
MOFs have emerged as ideal host materials for a wide range
of low molecular weight substances and bio-macromolecules.
MOFs are crystalline porous compounds based on metal ions or
clusters connected by organic ligands, which can be designed
into many different architectures and tailored for specific uses
by adjusting their topology, pore size and/or chemical
composition.[2,3] In recent years, nanoscale MOFs (nMOFs), are
being developed for bio-applications as they have much larger
effective surface areas than traditional MOFs, rendering them
improved chemical stability, more efficient surface modification
capabilities, and, in consequence, enhanced biological activity
of the respective composites.
The particle size of MOFs is determined by the nucleation
and growth rates in their synthesis. As a very simplified rule,
higher nucleation speed results in smaller particles. Therefore,
the synthetic conditions for the preparation of nMOFs must
favour nucleation over growth.[3]
nMOFs have the potential of forming stable colloids in
aqueous media essential for use as therapeutic carriers and
required for bioanalytical applications. A colloidal system can
flow like a liquid and therefore can be used in diagnostic assays
like ELISA and LFIA (Figure 1).[3] Despite the great advantages of
nMOFs, they suffer from weak resistance to moisture or
aqueous environment, owing to the facile decomposition of the
metal-ligand bonds. Metal-ligand bonds can be significantly
strengthened by the use of ligands rich in nitrogen, such as
imidazoles, which, on deprotonation, form imidazolate anions.[4]
Zeolitic imidazolate frameworks (ZIFs) are a subfamily of MOFs
formed by a self-assembly approach which consists of M-Im-M
units (with, e.g., M=Zn2+, Co2+, and Im= imidazolate linkers).[5]
Nanoscale ZIFs (nZIFs) display properties combining the advan-
tages of both zeolites and nMOFs, such as ultrahigh surface
areas, unimodal nanopores, high crystallinities, abundant
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functionalities, and exceptional thermal and chemical stabil-
ities.[5] We are most interested in those nZIFs that can form
colloids and present large cavities connected through small
windows, such as ZIF-8[3,6] and ZIF-90.[7] ZIF-8 chemical structure
is [Zn(2-mim)2] where 2-mim is 2-methylimidazolate and ZIF-90
is [Zn(i2ca)2] where i2ca is imidazolate-2-carboxaldehyde. Both
ZIFs present a sodalite-type architecture where Si/Al is replaced
with tetrahedral ZnII in ZIFs and O is replaced by their
corresponding imidazolate linkers.[3,7] ZIF-8[3,6, 8] and ZIF-90[7]
have been demonstrated to have permanent porosity, high
thermal stability, and remarkable chemical resistance to boiling
water, alkaline aqueous solutions, and organic solvents.[6]
Cravillon et al. found that excess ligand was essential for
promoting faster nucleation and stabilizing the initial colloids in
ZIF-8. The combination of excess ligand, methanol as solvent,
and room temperature has since formed the basis for most
syntheses of nanoscale ZIF-8 crystals.[9,10] Modulators are used in
the synthesis of ZIFs as capping agents. Modulators have two
opposing effects on the size of the ZIF particles: i) they can
increase the crystal size by competing with the organic ligands,
reducing the number of nucleation points, or ii) they can
decrease the crystal size by limiting crystal growth. It has been
established that reaction time, molar ratio, and reagent
concentration are critical parameters in tuning the size and
homogeneity of the desired colloidal ZIF-8 nanocrystals.[3]
Yaghi et al. demonstrated that the reactive aldehyde
functionalities in ZIF-90 were able to react with the primary
amino group of ethanolamine forming an imine in high yield
without significantly altering the original structural integrity.[7]
The strategy most predominantly used to date for post-
synthetic modification of MOFs is the treatment of a carboxylic
acid moiety with carbodiimide reagents such as 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) to form an activated
ester intermediate; this intermediate, on reaction with a primary
amine, results in the formation of a covalent amide link
between the MOF and the protein/antibody.[11–13]
The potential of nMOFs conjugated to antibodies as
bioanalytical probes has been demonstrated before,[11,14] but
not for n-MOFs. Their use bears the potential to expand the
application range combining the versatility of structure and
functionality of nMOFs with the selectivity and affinity of
antibodies.
Common particulate labels for antibodies suffer from poor
versatility of conjugation chemistry (as of nanogold) or from a
lack of distinct size, morphology, and stoichiometry (such as
with frequently used latex particles). We set up clear goals we
wanted to achieve when designing the antibody-conjugated
nMOF for proof of concept. 1) We needed the antibody-
conjugated nMOF to have good mobility so that it could be
used in ELISA and LFIA tests; 2) it had to retain the crystal
structure of the MOF while conserving the binding activity of
the antibody; 3) The link between nMOF and antibody had to
be relatively long, flexible and robust against cleavage, and 4)
the nature of the link should be such, that it could be confirmed
by LC-MS/MS following acid digestion of the antibody-con-
jugated nMOF.
We had recently published the synthesis of a luminescent
nano ZIF covalently linked to a fluorescent pyrene, referred as
Z8P, for the sensitive detection of phthalate plasticizers which
can act as endocrine-disrupting chemicals.[15] The fluorescent
nano Z8P has the pyrene fluorophore covalently linked via an
imine bond. Luminescent MOF (L-MOF) sensor materials
constraining analytes into the L-MOF cavity with appropriate
pore dimensions can lead to the pre-concentration of the
analytes resulting in high sensitivity and selectivity in
fluorescence sensing.[4] The fluorescence probe interaction with
analytes like phthalates,[15] or antibodies,[4,16] results in compet-
itive absorption, in which the analytes compete with the
luminescence probe material for excitation energy leading to
apparent emission quenching.
We present here the preparation of a bio-compatible
material based on the conjugation of nano zeolitic imidazolate
frameworks (nZIF) with antibodies (Figure 1). We specifically
selected ZIF-90 because of its reactive aldehyde functionalities
Figure 1. Top: Simplified scheme of the chemistry involved in forming a
covalent bond between ZIF-90 and a mouse IgG antibody resulting in a
stable ZIF-IgG conjugate. Middle: Characterization techniques for ZIF-anti-
body conjugates. Bottom: Two applications of the ZIF-antibody conjugate
particles: ELISA and LFIA.
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required to form imine bonds with lysine, this amino acid being
prevalent in all antibodies. By selectively reducing the imine
bond, a strong and flexible [  CH2  NH  CH2)4  ] link is formed.
This is the first time that such an antibody ZIF conjugate link is
reported. As a proof of concept, the nano-ZIF-90 antibody
conjugate is used on ELISA and LFIA bioanalytical method-
ologies.
We decided to investigate if the nano ZIF-90IgG conjugate
could tolerate the additional conjugation to a pyrene fluoro-
phore while maintaining its sodalite type nanostructure, its
mobility in aqueous solution, and biological activity without
detrimentally affecting the fluorescence activity of the fluoro-
phore.
The motivation for this research was to understand if this
ZIF-90 antibody conjugate with the additional fluorescence tag
could offer value to ELISA and LFIA bioanalytical procedures.
We hope to prove that the concept of a fluorescent tag,
incorporated in a ZIF, conjugated with an antibody, may one
day simplify immunoassays. We suggest that it may be feasible
to replace the conventional enzyme-labelled secondary anti-
body, that turns over a colorimetric substrate, with a simpler,
direct fluorescence readout. We also demonstrate that the
luminescence tag in a ZIF antibody conjugate can be useful in
lateral flow bioanalytical applications.
Results and Discussion
We selected nZIF-90, as it is the ideal ZIF for forming a good
conjugate with antibodies, based on the properties previously
discussed. For the antibody we selected to study immunoglo-
bulin G (IgG) as they are commercially available, inexpensive,
and sold as monoclonals of high purity.
A strong and robust linker requires a strong covalent bond
between ZIF and the antibody. This could be achieved if we
could form an initial imine bond between a lysine and an
aldehyde functionality installed on the ZIF, like in ZIF-90; this
imine could later be selectively reduced to   CH2  NH  obtaining
the desired 6-membered chain flexible link (Figure 1).
To do so, we first needed to synthesise ZIF-90 nanoparticles
in such a way that they could form a stable colloidal suspension
in aqueous media and be suitable for post-synthetic modifica-
tion with IgG to form an nZIF-90 antibody conjugate, referred
here as nZIF-90-IgG. This synthesis presented an immediate
challenge. Conventional modulators are used as capping agents
to achieve uniform nanosized ZIFs. The modulator n-butylamine
which had been used previously for the synthesis of nZ8P,[15]
would react via a Schiff base condensation with the imidazole-
2-carboxaldehyde (i2ca) ligand in ZIF-90. This condensation
between n-butylamine and the i2ca renders the aldehyde
functionalities of ZIF-90 no longer available for post-synthetic
modification with IgG. Instead, sodium methoxide (NaOMe) was
found to act as an excellent modulating agent without reacting
with the aldehyde functionalities in ZIF-90.
ZIF-90 nanoparticles were synthesized in methanol using
sodium methoxide as the modulating agent acting as a base to
deprotonate the i2ca to the respective imidazolate bridging
ligand. The details for the synthesis can be found in the
Experimental Section. This synthesis resulted in the formation
of non-aggregated nanoparticles in the size range of 30–
350 nm,[18,19] as confirmed by transmission electron microscopy
(TEM; Figure 2).[3] The corresponding powder X-ray diffracto-
gram (PXRD) shown in Figure 3a is consistent with a sodalite-
Figure 2. TEM pictures for ZIF-90. The rhombic dodecahedral shape of ZIF
particles[17] can be seen, with some polydispersity in size: between 30 and
350 nm and averaging 150 nm. These sizes were determined from TEM data
and are not absolute values.
Figure 3. Powder diffractograms for a) nZIF-90, b) the modified fluorescent ZIF-8/ZIF-90 hybrid [nZ8P], c) the nZIF-90-IgG conjugate [nZ90-IgG] and d) the
modified fluorescent ZIF-8/ZIF-90 hybrid-IgG conjugate [nZ8P-IgG].
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like crystalline structure. This infers that ZIF-90 has 2 equivalents
of i2ca  ligands per one equivalent of Zn2+.
The i2ca ligand in the ZIF-90 increases the hydrophilicity of
the ZIF, facilitating its dispersion in aqueous solutions.
As illustrated in Figure 1, we developed a plan to synthesize
nZIF-90-IgG, set a series of characterisation procedures, and
proposed potential bioanalytical applications like ELISA and
LFIA for investigation.
In order to synthesise nZIF-90-IgG, nZIF-90 was reacted with
IgG, resulting in the formation of an imine via Schiff base
conjugation between the ZIF-90 aldehyde functionality and the
(  CH2)4  NH2 pendant amine functionality of lysine in IgG. The
imine formed, could be selectively reduced, forming a strong
and flexible [  CH2  NH  CH2)4  ] link as schematically shown in
Figure 1.
Structural characterization of nZIF-90-IgG by LC-MS/MS
proved the successful covalent conjugation between the ZIF
i2ca moiety and the antibody through this robust link
[  CH2  NH  CH2)4  ]. To confirm the formation of this strong link,
the ZIF conjugates were acid digested (see Section 9.2 in the
Supporting Information) in order to cleave all amide bonds of
the peptide chains in IgG. At the same time, the acid digestion
broke the bonds between Zn and ligands in the ZIF releasing
the imidazolate ligands.
If the antibody was successfully covalently bound through a
lysine to ZIF-90, this cleavage would result in the release of l-
lysines covalently bound via an   NH  CH2  to imidazole, as
shown in Figure 4. A compound in agreement with this
structure was detected in its free form via liquid chromatog-
raphy high-resolution mass spectrometry (LC-HRMS; Figure 4).
The compound with a mass-to-charge ratio of 227.1503 was
present in both ZIF-IgG conjugates but absent in all exper-
imental controls (individually digested IgG and ZIFs without
conjugation). All major MS/MS fragments could be assigned to
substructures that explained the putative molecular structure
(Section 9.2 in the Supporting Information). Thus, covalent
bonding of an imidazole carboxaldehyde moiety to an amino
acid residue of the antibody is well supported by the results.
The structural integrity of the nZIF-90-IgG is critical to its
viability and so is its stability over time. Figure 3c is consistent
with nZIF-90-IgG having a sodalite-like crystalline structure
proving that the structure of ZIF-90 is conserved after
conjugation with IgG. The calculation of the Scherrer crystallite
sizes over time for both conjugates (Section 8.1 in the
Supporting Information) shows no change over time on the
crystallite sizes for the conjugates for up to 120 hours at 4 °C.
This is a strong evidence that the crystal structure of the ZIF
part of the ZIF-IgG conjugates does not suffer significant
damage over time.
Dynamic light scattering (DLS) studies in aqueous buffer is
used to determine the size of colloidal suspensions. Unlike
nanoparticle tracking analysis (NTA), DLS can severely over-
estimate the particle size of the sample. Larger particles are
preferably detected as they scatter much stronger than higher
concentrations of smaller particles. The DLS data for Z90-IgG
(Section 8.2 in the Supporting Information) is in the order of
1000–2000 nm, suggesting that Z90-IgG agglomerates at this
high concentration (100 μg/mL borate buffer), and can even
precipitate. However, this aggregation does not appear to be
detrimental to the storage (120 h at 4 °C) of nZ90-IgG at
concentrations of 200 and 750 μg/mL in borate buffer. This
aggregation is also easily reversible by a short sonication burst
(3–5 min).
Good mobility of nZIF-90-IgG in aqueous solution is critical
if these nanoparticles are to be used in bioanalytical applica-
tions. The mobility of nZIF-90-IgG in aqueous solution relies on
the formation of a stable colloidal suspension. These colloidal
suspension’s mobility is supported by NTA (Sections 8.2.3 and
8.2.4 in the Supporting Information).
NTA, a technique working at very low concentrations in
aqueous buffers is used to determine the size of colloidal
suspensions. Unlike DLS, it allows small particles to be much
more visible than large particles of the same sample as
compared with DLS. It provides individual particle sizing,
intensity distribution, and approximate concentrations. NTA
data for ZIF-90-IgG prepared at similar concentrations as
typically used for ELISA bioanalytical studies (10 to 20 μg/mL
borate buffer), shows a rather broad size distribution with most
particles being between 30–350 nm, (Section 8.2.3 in the
Supporting Information). This size distribution is consistent with
the TEM analysis of nZIF-90 (Figure2).
To investigate the fluorescence of nZIF antibody conjugate
biomaterial, we needed first to synthesise the Z8P nano-
particles. We modified a ZIF-8/ZIF-90 hybrid to be fluorescent
by including an aminopyrene core. For this, a fluorescent imine
compound is initially formed, referred here as “imine”, by
reacting 1-aminopyrene (1-AP) with i2ca via Schiff base
condensation. This in situ formed “imine” together with excess
of i2ca and 2-min was reacted by solvothermal procedure using
sodium methoxide as the capping agent. NaOMe was used for
the same reasons as explained for the synthesis of nZIF-90. The
hybrid ZIF is precipitated obtaining the fluorescently modified
ZIF (nZ8P) which contains three imidazolate ligands (i2ca, 2-
Figure 4. Mass spectrometric evidence of assumed covalent bonding in the
ZIF-90-IgG conjugate. The MS/MS spectrum shows a putative lysine
derivative (precursor m/z 227.1503, isolation window 1 Da).
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mim and the ”imine”). Details for the synthesis can be found in
the Experimental Section.
The synthesis of nZ8P resulted in the formation of nano-
particles in the size range of 50–150 nm,[18,19] as confirmed by
TEM; (Figure 5).[3] These particles are smaller than those from
nZIF-90 as 2mim is more reactive than i2ca, deprotonating
more easily and leading to the formation of smaller nano-
particles. The corresponding PXRD (see Figure 3b) is consistent
with a sodalite-like crystalline structure.
The ratio of ligand-to-metal in Z8P must be 2.0 as inferred
from the PXRD being consistent with a sodalitetype structure.
However, the proportion between the three imidazolate ligands
(i2ca, 2-mim and ”imine”) in Z8P has to be determined by HPLC
analysis (Section 5.2 in the Supporting Information) while the
concentration of Zn2+ in Z8P can be determined indirectly from
the HPLC characterization, as well as directly by ICP-OES analysis
(Section 5.3 in the Supporting Information). The HPLC data,
supported by the ICP data, confirms a molar ratio of 2.0
between the imidazolates and the Zn2+ in Z8P. The authors
have previously published, for the first time, the chemical
analysis of frameworks by HPLC.[15,20]
Notably, the final composition of Z8P by HPLC is consistent
with 2-mim being included on the composition of the hybrid
fluorescent ZIF, as required to achieve the desired nano-
structure. HPLC analysis supports that most of the imidazolate
moieties in Z8P are i2ca which are those that include the
aldehyde functionality. This high share of i2ca in Z8P offers
suitable binding sites for the antibodies. We can consider Z8P
as a ZIF hybrid with approximately 3 :1 of ZIF-90 over ZIF-8 as
the imidazolate ligands in ZIF-90 are exclusively i2ca while
those in ZIF-8 are exclusively 2-mim.
As in the case of ZIF-90 previously discussed, i2ca in Z8P
increases the hydrophilicity of the ZIF, facilitating its dispersion
in aqueous solutions.
The same post-synthetic methodology depicted in Figure 1
is used to prepare nZ8P-IgG. The free aldehyde functionalities
of nZ8P are reacted with IgG, resulting in the formation of a
Schiff base. The selective reduction of the imine bond resulted
in the formation of a strong and flexible link [  CH2  NH  CH2)4  ]
between the Z8P and the antibody. The sodalite structure from
nZ8P is being retained upon the formation of nZ8P-IgG as
supported by PXRD (Figure 3d). The particle size of nZ8P
although retained in nZ8P-IgG (Figure S29 in the Supporting
Information), shows agglomeration as it is prepared at high
concentrations and in MeOH, a poor dispersant. The crystal
structures and corresponding particle sizes of nZ8P-IgG remain
intact for up to 120 hours at 4 °C based on PXRD investigations
(Section 8.1 in the Supporting Information), as previously
discussed for nZIF-90-IgG.
We have demonstrated here that both nZIF-90-IgG and
nZ8P-IgG conserve their sodalite-like crystalline structure after
conjugation. Their nanosized particle range allows them to
form stable colloidal suspensions in aqueous media as
supported by NTA and DLS experiments.
The first important property to be conserved during
conjugation of ZIFs to antibodies is the binding properties of
the conjugated IgGs in terms of affinity and selectivity. The
second important property of the conjugates is that they
should be highly mobile in dispersion (for ELISA applications) as
well as mobile in lateral flow on a solid matrix (for LFIA
applications, e.g. on polyvinylidene difluoride (PVDF) mem-
branes).
In a conventional indirect non-competitive ELISA, the bind-
ing of the antibody is quantified by adding an enzyme-labelled
secondary antibody that turns over a colorimetric substrate.
Employing nZIF-90-IgG and nZ8P-IgG in this model, ELISA
resulted in the expected sigmoidal curves (Figure 6). This proves
that the antibodies in nZ90-IgG and nZ8P-IgG retained their
binding properties. The successful application of nZIF-90-IgG to
ELISA is also a strong pointer towards their mobility; the
reproducibility on each replicate requires to be low for good
mobility (Figure S20 in the Supporting Information, error bars
for Z8P-IgG and Z90-IgG).
An important feature to be retained in nZ8P-IgG, is that its
fluorescence must be conserved in the presence of the
conjugate antibody, so that these biomaterials could be
employed in fluorescence immunoassays and/or fluorescence
quenching assays. We tested the response of nZ8P-IgG against
various concentrations of dimethyl phthalate (DMP) in order to
check if fluorescence quenching was conserved in comparison
to the unconjugated Z8P (Section 5.1 in the Supporting
Information). The presence of antibodies around the Z8P
nanoparticles proved not to interfere with this mechanism,
nZ8P-IgG was still sensitive to quenching by short-chained
phthalates; the fluorescence intensity as a function of the
concentration of dimethyl phthalate was determined. A
response comparable to the one reported previously by us for
this system was recorded (Figure S10 in the Supporting
Information).[15]
Figure 5. TEM images of nanoparticulate Z8P. a) rhombic dodecahedra characteristic for SOD ZIF systems; b), c) The particles show a polydispersity. c) EDX
analysis confirms the presence of Zn (purple).
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To turn the enzyme immunoassay into a fluorescence
immunoassay based on the inherent fluorescent properties of
Z8P, the model non-competitive indirect ELISA was performed
at higher concentrations (Sections 7.4.1 and 7.4.2 in the
Supporting Information).
Fluorescence measurements (λex=335 nm) on this system
resulted in low fluorescence emission intensities. After a
washing step to remove loosely bound Z8P particles, the assay
gave even lower intensities (Figure 7). This drop in fluorescence
intensity is partly due to all the non-conjugated Z8P particles
being removed. Only those Z8P which were conjugated to
antibodies remained retained on the surface of the microtiter
plate (MTP). After the addition of an acidic buffer, that
protonates the imidazolate buinding blocks and breaks down
the ZIFs, a significant increase in fluorescence can be seen. We
believe this to be evidence of the inner-filter quenching[21] that
is happening on the Z8P ZIF nanoparticles being eliminated
once the ZIF particles were broken dowin to its constituents.
This inner filter effect has also been reported for other nano-
carrier systems such as liposomes.[22]
As for the nature of the quenching itself, when considering
the characteristics of the absorption spectra for DMPs[23] and for
the imidazolate species forming the modified ZIF (UV absorp-
tion spectra, Figure S11 in the Supporting Information) suggests
that they do not absorb at the wavelengths involved in the
fluorescence spectra (excitation at 288 nm and emission of the
imine within the Z8P ZIF between 400 and 540 nm (Figure S10a
in the Supporting Information)). Therefore, it must be assumed
that the quenching is not due to quenching effects by
absorption of the emitted radiation by the imine. Instead, we
believe a π- π stacking that leads to the formation of an exciton
state, does no longer absorb radiation. This excimer could be
formed in the bulk of the Z8P particles, since DMP could diffuse
through the pores of the ZIF and become trapped in the cavity
with the pyrene moiety part of the imines.
The effect that the antibodies exert on the Z8P particles’
surface is more difficult for us to say. It is likely that the
antibodies can absorb part of the incident excitation radiation,
as well as quenching the fluorophores on the surface via
excimer formation (some amino acids have aromatic moieties).
A more detailed explanation can be found in Section 5.1 in the
Supporting Information.
We appreciate that aminopyrene is not optimal for
fluorescence detection because the MTP material used in ELISA
also absorbs light in the UV range. As Z8P-IgG was only
investigated as a proof of concept, we did not search for an
improved fluorescence tag, as the optimisation of this fluo-
rophore was outside our objectives.
Z8P-IgG was tested for its suitability for applications in LFIA.
To facilitate this LFIA test and to eliminate the need of one
additional antibody carrying the HRP probe, another Z8P-IgG
conjugate, nZ8P-IgG-HRP was synthesised. Details for the syn-
thesis can be found in the Experimental Section. We employed
a commercially available anti-sheep IgG-HRP conjugate. The
synthesis of nZ8P-IgG-HRP is analogous to nZ8P-IgG (Sec-
tion 10.1 in the Supporting Information).
The only significant advantage of using Z8P-IgG over Z90-
IgG is for the validation of the LFIA bioanalytical assay. The
emission of the fluorescence pyrene tag at the antibody capture
zone demonstrates that IgG must travel as a conjugate with the
ZIF. To prove so, this zone was cut and digested with sulphuric
acid, to release the fluorophore 1-aminopyrene. Dependent on
Figure 6. Proving the integrity of the ZIF-IgG conjugate: Results from a
noncompetitive ELISA. Unmodified anti-mouse IgG (from sheep) used as
reference (*), Z8P-IgG (■) and Z90-IgG (◆). HRP: horseradish peroxidase.
Figure 7. Fluorescence emission for the noncompetitive indirect assay
employing Z8P-IgG (λex=335 nm). Prewash fluorescence with excess nZ8P-
IgG (◆), post wash (■), and released aminopyrene fluorophore (*) from acid
hydrolysis of the imine.
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the amount of Z8P-IgG employed (and thus captured),
fluorescence was observed (Figure 8).
Aggregation as demonstrated by DLS is also not detrimental
to the mobility of nZ8P-IgG across the PVDF solid matrix at high
particle concentrations (750 μg/mL borate buffer). The mobility
of nZ8P-IgG is only stopped at the antibody capture zone.
During the LFIA elution of the Z8P-IgG dispersion, the presence
of the antibody conjugate in the capture zone is detected by
the HRP colour change as well as the presence of the nZ8P is
proven by the fluorescence of its pyrene conjugate.
Conclusion
This is the first time that the formation of a stable covalent
linkage of an antibody conjugated to a zeolite imidazolate
framework (ZIF) has been demonstrated. These ZIF-antibody
conjugates have been extensively characterised, demonstrating
that all the properties of its constituent parts, ZIFs and
immunoglobulins, are retained. In addition to preserving the
mobility of the nanoparticulate entity, the conjugation also
prevents protein aggregation of the antibodies at low aqueous
concentrations and, like an exoskeleton, might elicit protection
against degradation. These ZIF antibody conjugates with
tailored mobility drastically expand the potential of ZIFs to be
applied as highly selective bioprobes in a variety of analytical
and diagnostic applications, such as enzyme-linked immuno-
sorbent assay (ELISA) and lateral flow immunoassay (LFIA). Our
findings should be of interest in the development of better
portable formats, a key aspect gaining importance in the
scientific confrontation with global diseases and pandemics.
Experimental Section
Preparation of the 1-aminopyrene-functionalized nanoparticu-
lated ZIF-8/ZIF-90hybrid (Z8P): 16.08 mg (0.075 mmol) of 1-amino-
pyrene (1-AP) and 47.28 mg (0.493 mmol) of imidazolate-2-carbox-
aldehyde (i2ca) were added to a sealable glass flask, 5 mL of
methanol was added, the glass flask was sealed with an aluminium
cap and heated at 80 °C for 30 min with stirring. After cooling to
ambient temperature, 40.4 mg (0.493 mmol) of 2-methylimidazole
(2-mim) and 250 μL of a nearly saturated solution of MeONa in
methanol (0.25 g/mL) were added. 5 ml of a Zn(NO3)2 · 6·H2O
solution (146 mg of Zn(NO3)2 · 6·H2O (0.494 mmol) in 10 mL of
methanol) was added. A yellow precipitate appeared which was left
for 4 h undisturbed, and later taken through an extensive washing
procedure to remove unbound compounds forming ZIF-8/ZIF-90
hybrid (Z8P). For more in-depth information see Section 4.1 in the
Supporting Information.
Preparation of nanoparticulated nZIF-90-IgG: 1.5 mL of a borate
buffer solution was added to 1.5 mg of the ZIF-90, the vial was
sealed and sonicated. 50 μL of a 2 mg/mL solution of sheep anti-
mouse IgG was added. 50 μL of Na[BH3(CN)] (5 M in 1 M NaOH) was
added and allowed to react for 4 h at RT. For more in-depth
information see Section 6.1 in the Supporting Information. ZIF-8P-
IgG is used for ELISA bioanalysis.
CAUTION! Na[BH3(CN)] is volatile and extremely toxic when inhaled
or in contact with the skin.
Preparation of nanoparticulated Z8P-IgG-HRP: 1.5 mL of a borate
buffer solution was added to 1.5 mg of the Z8P, the vial was sealed
and sonicate. 50 μL of a 1.8 mg/mL solution of anti-sheep IgG-HRP
was added. 50 μL of Na[BH3(CN)] (5 M in 1 M NaOH) was added and
allowed to react for 4 h at RT. For more in-depth information see
Section 10.1 in the Supporting Information. Z8P-IgG-HRP is used for
LFIA bioanalysis.
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Framing an assay: We present
nanosized zeolitic imidazolate frame-
works (ZIFs) conjugated to immuno-
globulin G (IgG) antibodies by using a
strong and flexible covalent amino-
alkyl link. These nanoZIF-IgG particles
display good mobility and an
excellent behaviour in dispersion.
Their application to antibody-based
bioanalytical assays, including
enzyme-linked immunosorbent assay
(ELISA) and lateral flow immunoassay
(LFIA), was examined.
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